Sodium–glucose co-transporter-2 inhibitors for hospitalised patients with COVID-19: a prospective meta-analysis of randomised trials

Sodium–glucose co-transporter-2 inhibitors for hospitalised patients with COVID-19: a prospective meta-analysis of randomised trials

<p><b>Background</b></p> Sodium–glucose co-transporter-2 (SGLT2) inhibitors have been proposed as a potential treatment for adults hospitalised with COVID-19, due to their potential anti-inflammatory and endothelial protective effects. Published evidence from randomised contr...

Full description

Bibliographic Details
Main Authors: Vale, C, Godolphin, PJ, Fisher, D, Horby, PW, Kosiborod, MN, Hochman, JS, Webster, K, Higgins, JPT, Althouse, AD, Berwanger, O, Furtado, RHM, Gasparyan, SB, Haynes, R, Koch, GG, Landray, M, Leifer, E, Marshall, J, Murthy, S, Neal , M, Staplin, N, Diaz, J, Sterne, JAC, Shankar-Hari, M
Other Authors: WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group
Format: Journal article
Language:English
Published: Elsevier 2024

Similar Items